The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Assessing EFGR TKIs in patients with wild-type EFGR NSCLC
Joshua K. Sabari, MD, NYU Langone Health, New York, NY, comments on the use of EFGR tyrosine kinase inhibitors (TKIs) in patients with wild-type EFGR non-small cell lung cancer (NSCLC). Whilst TKIs are usually administered in patients with exon 19, 20, or 21 mutations, these class of drugs have variable efficacy in patients with wild-type EFGR NSCLC. However, antibody-drug conjugates targeting EFGR may be a promising therapeutic option for these group of patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
